Oncology
Recurrent Head and Neck Cancer
2
Pipeline Programs↗
3
Active Trials↗
9
Companies Involved↗
Recurrent Head and Neck Cancer is an early-stage landscape with 2 programs across 9 companies. The most active players are AstraZeneca, Imclone, Eastern Cooperative Oncology Group.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
46
clinical trials
Completed25 · 54%
Terminated10 · 22%
Unknown status6 · 13%
Withdrawn2 · 4%
Recruiting2 · 4%
Active, not recruiting1 · 2%
Clinical Trials
Trial Activity
46 trials
Boron Neutron Capture Therapy With B10 L-BPA for Unresectable Recurrent Head and Neck Cancers
Recruiting·—·Phase 2·NCT06952868·24 enrolled
Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00022594·50 enrolled
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Completed·—·Phase 1·NCT01163487·17 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)